VERSAMEB
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational since 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab ben... ch to patient. Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts. The pipeline includes lead candidate programs in stress urinary incontinence (SUI), solid tumors and rare diseases. Versameb is working towards the completion of a first in-human proof-of-concept clinical study while advancing its platform.
VERSAMEB
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2017-07-31
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.versameb.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
26.65 M CHF
Technology used in webpage:
Google Maps Amazon Google Maps API Pound Sterling Amazon Frankfurt Region FreshService Hostpoint
Similar Organizations
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Evaxion Biotech
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.
Rapt Therapeutics
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Holiferm
Holiferm develops holistically improved fermentation technology for massive economic improvements.
New Amsterdam Pharma
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
PolyModels Hub
Accelerate drug development with modeling, simulations, and data
Spexis
Spexis is a swiss pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.
UniQure
uniQure is focused on the research and early development of human gene-based therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Key Employee Changes
| Date | New article |
|---|---|
| 2023-06-21 | Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer |
Official Site Inspections
http://www.versameb.com Semrush global rank: 3.96 M Semrush visits lastest month: 2.78 K
- Host name: sl2199.web.hostpoint.ch
- IP address: 217.26.55.168
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Versameb"
versameb - versameb
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us …See details»
Versameb - Crunchbase Company Profile & Funding
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to …See details»
Team - versameb
The Versameb team consists of a number of senior experts in drug development and business building, complemented by a strong advisory team with research, clinical, technical and …See details»
Versameb AG - Swiss Biotech
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in …See details»
Versameb Company Profile 2024: Valuation, Funding & Investors
1. General Information. Description. Operator of a biotechnological research firm intended to focus on discovering and developing innovative RNA-based drugs for modulation of protein …See details»
Versameb AG - Drug pipelines, Patents, Clinical trials - Synapse
The pipeline includes lead candidate programs in stress urinary incontinence (SUI), solid tumors and rare diseases. Versameb is working towards the completion of a first in-human proof-of …See details»
Versameb - VentureRadar
Website: https://versameb.com/ Develops innovative RNA-based drugs for protein modulation, cellular targeting, and therapeutic target influence in dermatology, oncology, and myology …See details»
Versameb Announces Management Update - PR Newswire
BASEL, Switzerland, Jan. 8, 2021 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, …See details»
Versameb AG - top100startup.ch
Oct 17, 2019 · Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business team. The company’s focus is the development of novel RNA-based …See details»
company - versameb
Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, including the …See details»
Versameb AG Announces FDA Clearance of IND Application for …
BASEL, Switzerland, Nov. 16, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, …See details»
Versameb - Products, Competitors, Financials, Employees, …
Versameb is a biotechnology company that focuses on the discovery and development of innovative RNA-based drugs. The company's main offerings include the development of drugs …See details»
Versameb raises CHF 6 million and strengthens team to advance …
Jul 15, 2020 · Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round.See details»
Versameb to present novel data on its lead asset, VMB-100 at 9th ...
Nov 4, 2021 · Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs, today announces that its Chief Scientific Officer, …See details»
Versameb raises 6 million Swiss francs
Jul 17, 2020 · Using revenues obtained from a seed financing round totaling 6 million Swiss francs, Versameb is planning to bring its VERSagile platform to the clinical development stage …See details»
Versameb AG Announces FDA Clearance of IND Application for …
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug …See details»
Versameb presents data on mRNA treatment for Stress Urinary ...
Nov 9, 2021 · RNA engineering technology enhances the potency of mRNA. Versameb has developed a groundbreaking RNA technology platform, VERSagile, and is building a pipeline …See details»
Technology - versameb
Expression of disease-relevant proteins can be achieved by molecular targeting of a specific gene through mRNA. Versameb’s technology aims to use mRNA to direct a patient’s cells to …See details»
Versameb: FDA clearance for stress urinary incontinence …
Nov 16, 2023 · Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. …See details»
Pipeline - versameb
The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept …See details»